Latest Period
Q1 2026
Security Snapshot
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) Institutional Ownership
CUSIP: 03237H101
13F Institutional Holders and Ownership History from Q1 2022 to Q1 2026
Institutions Reporting
170
Shares (Excl. Options)
114,149,868
Price
$13.90
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- AMLX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 114,149,868
- Total 13F value
- $1,586,300,963
- Portfolio coverage rank
- 0%
- Share change
- +259,383
- Value change
- +$10,726,660
- Number of holders
- 170
- Shares outstanding
- 110,465,093
- SEC-reported price per share
- $14.44
- Insider filing price
- $14.44
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 03237H101.
- 170 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 181 to 170 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,356,917,552 to $1,586,300,963.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 170 institutions filings for Q1 2026.
Security key
03237H101
Latest holder period
Q1 2026
13F holders
170
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
AMLX full holder history
Amylyx Pharmaceuticals, Inc. SEC filings
Amylyx Pharmaceuticals, Inc. company facts
Amylyx Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03237H101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
AMLX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +39% | $198,938,502 | +$61,477,681 | 16,468,419 | +45% | FMR LLC | 31 Dec 2025 |
| PERCEPTIVE ADVISORS LLC | 7.5% | -8.8% | $136,452,007 | -$10,993,445 | 8,284,882 | -7.5% | Perceptive Advisors LLC | 31 Mar 2026 |
| BlackRock, Inc. | 7.1% | +32% | $94,027,246 | +$34,623,342 | 7,783,648 | +58% | BlackRock, Inc. | 31 Dec 2025 |
| TCG Crossover GP II, LLC | 5.7% | $74,863,306 | 6,243,812 | TCG Crossover GP II, LLC | 31 Dec 2025 | |||
| Commodore Capital LP | 5.1% | $89,213,500 | 5,650,000 | Commodore Capital LP | 10 Nov 2025 | |||
| Point72 Asset Management, L.P. | 2.6% | -54% | $38,074,233 | -$26,039,432 | 2,801,636 | -41% | Point72 Asset Management, L.P. | 30 Sep 2025 |
| Adage Capital Management, L.P. | 2.5% | -64% | $33,296,889 | -$48,436,878 | 2,777,055 | -59% | Adage Capital Management, L.P. | 31 Dec 2025 |
| Panacea Innovation Ltd | 2.6% | $11,792,000 | 2,200,000 | Panacea Venture Healthcare Fund II, L.P. | 31 Dec 2024 |
As of 31 Mar 2026, 170 institutional investors reported holding 114,149,868 shares of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX). This represents 103% of the company’s total 110,465,093 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
85%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 16,630,541 | +0.68% | 0.01% | $231,164,520 |
| BlackRock, Inc. | 8% | 8,828,836 | -2.5% | 0% | $122,720,817 |
| PERCEPTIVE ADVISORS LLC | 7.5% | 8,284,882 | 0% | 2.3% | $115,159,860 |
| TCG Crossover Management, LLC | 5.7% | 6,243,812 | 0% | 2.5% | $86,788,987 |
| Commodore Capital LP | 5.1% | 5,650,000 | 0% | 4.5% | $78,535,000 |
| JANUS HENDERSON GROUP PLC | 4.5% | 4,986,073 | +12% | 0.03% | $69,256,554 |
| Saturn V Capital Management LP | 3.9% | 4,349,885 | -3.3% | 11% | $60,463,402 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 4,141,575 | 0% | 0% | $57,567,893 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.2% | 3,560,764 | +28% | 0.08% | $49,494,620 |
| First Light Asset Management, LLC | 2.9% | 3,190,645 | -4.9% | 4% | $44,349,966 |
| Driehaus Capital Management LLC | 2.7% | 2,987,147 | -3.9% | 0.31% | $41,521,343 |
| GOLDMAN SACHS GROUP INC | 2.4% | 2,625,991 | +0.49% | 0% | $36,501,275 |
| STATE STREET CORP | 2.1% | 2,363,161 | +14% | 0% | $32,847,938 |
| FRANKLIN RESOURCES INC | 2% | 2,261,569 | +88% | 0.01% | $31,435,812 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,210,932 | +2.1% | 0% | $30,736,816 |
| MORGAN STANLEY | 2% | 2,175,546 | -7.8% | 0% | $30,240,090 |
| Almitas Capital LLC | 1.9% | 2,122,597 | 0% | 6.7% | $29,504,098 |
| GREAT POINT PARTNERS LLC | 1.6% | 1,750,000 | 0% | 6% | $24,325,000 |
| Jones Hill Capital LP | 1.4% | 1,598,794 | 0% | 4.8% | $22,223,237 |
| 683 Capital Management, LLC | 1.4% | 1,530,000 | -7.3% | 2% | $21,267,000 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.4% | 1,513,958 | +0.05% | 0.35% | $21,042,311 |
| BANK OF AMERICA CORP /DE/ | 1.2% | 1,330,689 | -0.4% | 0% | $18,496,577 |
| DEUTSCHE BANK AG\ | 1.1% | 1,267,785 | -4.9% | 0.01% | $17,622,212 |
| Siren, L.L.C. | 1.1% | 1,230,000 | 0.47% | $17,097,000 | |
| Balyasny Asset Management L.P. | 1% | 1,107,271 | +29% | 0.03% | $15,391,067 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
17
Latest
Q1 2026
Rows shown
1-17 of 17
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 114,149,868 | $1,586,300,963 | +$10,726,660 | $13.90 | 170 |
| 2025 Q4 | 112,323,168 | $1,356,917,552 | +$21,178,269 | $12.08 | 181 |
| 2025 Q3 | 109,720,694 | $1,491,122,082 | +$396,029,872 | $13.59 | 168 |
| 2025 Q2 | 81,690,006 | $523,632,250 | +$57,316,535 | $6.41 | 131 |
| 2025 Q1 | 73,877,500 | $261,528,744 | +$85,099,354 | $3.54 | 134 |
| 2024 Q4 | 49,784,011 | $188,180,501 | +$19,458,443 | $3.78 | 120 |
| 2024 Q3 | 43,406,257 | $140,608,833 | +$5,128,506 | $3.24 | 107 |
| 2024 Q2 | 43,632,024 | $82,904,189 | -$16,885,307 | $1.90 | 115 |
| 2024 Q1 | 49,485,594 | $140,539,742 | -$234,955,037 | $2.84 | 138 |
| 2023 Q4 | 60,281,638 | $887,348,868 | -$11,902,243 | $14.72 | 177 |
| 2023 Q3 | 58,927,724 | $1,078,966,869 | +$84,065,478 | $18.31 | 168 |
| 2023 Q2 | 54,545,075 | $1,176,653,052 | +$56,163,167 | $21.57 | 153 |
| 2023 Q1 | 51,372,917 | $1,507,231,117 | +$73,671,274 | $29.34 | 145 |
| 2022 Q4 | 48,572,530 | $1,794,757,212 | +$422,522,242 | $36.95 | 131 |
| 2022 Q3 | 36,858,311 | $1,037,561,470 | +$315,174,073 | $28.15 | 90 |
| 2022 Q2 | 26,621,859 | $512,910,346 | +$65,322,870 | $19.26 | 74 |
| 2022 Q1 | 23,420,880 | $299,935,403 | +$299,912,422 | $12.85 | 72 |